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Abstract: Quercetin is a flavonol, also a phytoestrogen, available commonly in onion and apple. Our laboratory investi-
gated its effect on MC3T3-E1 cells’ alkaline phosphatase activity in vitro and compared the amount of new bone pro-
duced by quercetin in collagen matrix to that produced by bone grafts and collagen matrix in vivo. Four bone defects, 
5mm by 10mm were created in the parietal bone of 2 New Zealand White rabbits. In the experimental animal, 2 defects 
were grafted with quercetin solution mixed with collagen matrix. In the control animal, 2 defects were grafted with colla-
gen matrix alone. Animals were killed on day 14 and the defects were dissected and prepared for histological qualitative 
assessment. Results showed that 10μM of quercetin increased alkaline phosphatase activity of MC3T3-E1 cells at 72 
hours in vitro by 32%. In the experimental animal, there was new bone growing inside the bone defects. In conclusion, 
specific concentration of quercetin increased alkaline phosphatase activity of MC3T3-E1 cells in vitro and quercetin in 
collagen matrix has the effect of forming new bone across bone defects in vivo. 
Keywords: Bone repair, flavonol, phytoestrogen, quercetin. 
INTRODUCTION 
 Discovery of chemicals that increase bone formation is 
needed for the treatment of osteoporosis or to improve bone 
healing after trauma or surgery. The decrease in serum estro-
gen after menopause is associated with bone loss and osteo-
porosis, and estrogen replacement therapy is considered to 
be effective in preventing bone loss (Turner ER 1994) [1]. It 
has been shown that estrogen enhances osteoblast differen-
tiation and bone formation (Qu Bone 1998) [2] and the con-
ditioned medium of estrogen-treated osteoblast cultures in-
hibits osteoclast development (Qu Bone 1999) [3]. Although 
there are concerns about the effectiveness of oestrogen re-
placement therapy in the prevention of osteoporosis, estro-
gen is one of the most important sex steroids for the mainte-
nance of bone balance. 
 Phytoestrogens are plant-derived non-steroidal com-
pounds that bind to estrogen receptors (ERs) and have estro-
gen-like activity (Branca PNS 2003) [4]. Phytoestrogens 
have attracted much attention among public and medical 
communities because of their potential beneficial role in pre-
vention and treatment of cardiovascular diseases, osteoporo-
sis, diabetes and obesity, menopausal symptoms, renal dis-
eases and various cancers (Hathena AJCN 2002) [5] 
(Duncan BPRCEM 2003) [6].
 
 Phytoestrogens are divided into three classes: isofla-
vones, coumestans and lignans. In addition, some flavonoids, 
such as flavonols, are also classed as phytoestrogens 
(Duncan BPRCEM 2003) [6]. Estrogen receptors exist as 
two subtypes, ERa and ERb, and osteoblasts express both 
receptors (Arts Endocrinology 1997) [7]. The interaction 
between flavonols and flavonoids with ERa and ERb is well  
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documented (Kuiper Endocrinology 1998) [8]. Kuiper et al.  
(Kuiper Endocrinology 1998) [8],
 
who studied the estrogenic 
potency of several phytoestrogens, showed that quercetin 
 have the capacity to bind both ER subtypes. 
 Quercetin, 3,3',4',5,7-Pentahydroxyflavone; 2-(3,4-
Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one, 
C15H10O7, molecular weight: 302.24, water solubility: <0.1 
g/100 mL at 21°C, is one of the major phytoestrogens iso-
lated from onion (200-600mg quercetin/kg onion) (Price 
JSFA 1997) [9],
 
apple and grape. The average daily flavon-
oid intake in the occidental diet is around 23 mg, of which 
quercetin represents 60% to 75% (Hertog Lancet 1993) [10].
 
 Kanno et al. (Kanno Toxicology 2004) [11] report the 
effects of phytoestrogens and environmental estrogens on 
osteoblast differentiation using MC3T3-E1 cells, a mouse 
calvaria osteoblast-like cell line. They increased alkaline 
phosphatase activity and enhanced bone mineralization in 
these cells. It is possible that quercetin also stimulates os-
teoblasts and increases the bone formation locally. 
 Therefore, if quercetin, this common constituent in fruits 
and vegetables, can be shown to increase bone forming ac-
tivities in bone cells and improve healing in bone defects, it 
may be the long-sought-after safe and ideal agent for stimu-
lation of bone formation and bone defect repair. The aims of 
this study were to examine quantitatively the effects of quer-
cetin on MC3T3-E1 cells, a mouse calvaria preosteoblastic 
cell line and qualitatively the effect of quercetin on bone 
defects in vivo. 
MATERIALS AND METHODOLOGY 
 Cell culture: MC3T3-E1 mouse perosteoblasts (RIKEN, 
Japan) were cultured in Alpha Minimum Essential Medium 
MEM? (Invitrogen, USA) containing 10 vol% fetal bovine 
serum (Invitrogen, USA) and antibiotics penicillin G sodium 
100 units/mL and streptomycin 100μL/mL (Invitrogen, 
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USA) and incubated at 37°C in a 5% CO2/95% air humidi-
fied atmosphere (Declercq Biomaterials 2005) [12]. 
 Control Group: Cells cultured without any intervention 
for different time intervals (24 hours, 48 hours and 72 hours 
and 14 days for mineralization). 
 Quercetin Group: Cells cultured with quercetin (Sigma, 
USA) of different concentrations (0.1μM, 1μM, 10μM and 
100μM) for different time intervals (24 hours, 48 hours and 
72 hours and 14 days for mineralization). 24 and 96-well 
tissue culture plates (Iwaki, Japan; 2.5?104cells/cm2) were 
used. Each experimental condition was repeated 4 times. 
Cytoplasmic total protein assay: Total protein is an indica-
tion of the proliferative and biosynthetic capacities of bone 
cell cultures. Cells in 24 well plates were lysed and the cellu-
lar material was removed into 250μL of a buffer containing 
10mM Tris HCl pH 7.5, 0.5mM MgCl2 and 0.1% Triton X-
100. The cellular material was homogenized by two freeze-
and-thaw cycles (Declercq Biomaterials 2004) [13]. The 
cellular protein concentration was determined by BCA pro-
tein assay kit (Pierce, IL, USA). 
 Biochemical detection of the alkaline phosphatase activ-
ity: The protocol of Declercq et al. (Declercq Biomaterials 
2004) [13] was followed. After rinsing the monolayers in 24 
well plates with Ringer solution, the cellular material was 
removed after lysis into 250 μL of a buffer containing 10 
mM Tris HCl pH 7.5, 0.5 mM MgCl2 and 0.1% Triton X-
100. The cellular material was homogenized by two freeze-
and-thaw cycles. Alkaline phosphatase activity was deter-
mined with p-nitrophenylphosphate as the substrate. Sample 
volumes of 50 μL were added to 50 μL p-
nitrophenylphosphate (4.34 mM) in 100 mM glycine, pH 
10.3, 1 mM MgCl2 and incubated at 37°C for 30 min on a 
bench shaker. The enzymatic reaction was stopped by adding 
50 μL of 1M NaOH. Enzyme activity was quantified by ab-
sorbance measurements at 405 nm and calculated according 
to a series of alkaline phosphatase standards. Alkaline phos-
phatase activity was expressed as unit of alkaline phospha-
tase/mg protein. 
 Statistical analysis: Data were analysed with a statistical 
analysis computer software (SPSS 15.0 for Windows©, 
SPSS Inc., Chicago, Illinois 60606). Data were performed 
with normality test (Kolmogorov-Smirnov test; p>0.05). The 
unpaired t-tests with Welch correction were used to compare 
with control and different concentrations of quercetin. Sig-
nificance was set in advance at p<0.05. 
 In vivo qualitative study of quercetin in bone defect: The 
methodology and animal model used have been described 
previously (Wong BJOMS 2003) [14]. Four 10?5 mm2 full-
thickness bone defects were created in the parietal bones of 2 
New Zealand White rabbits from an inbred colony. The rab-
bits were 5 months old (adult stage) and weighed 3.5-4.0kg. 
The handling of the animals and the experimental protocol 
were approved by the Committee on the Use of Live Ani-
mals in Teaching and Research, the University of Hong 
Kong. In the experimental animal, 2 defects were grafted 
with collagen matrix carrier with quercetin solution. In the 
control animal, 2 defects were grafted with collagen matrix 
alone. The animals were premedicated 1 hour before surgery 
with oxytetracycline hydrochloride (200mg/mL, 30mg/kg 
body weight, Tetroxyla, Bimeda, Dublin, Ireland) and bu-
prenorphine hydrochloride (0.3mL/kg body weight, Hyp-
norm, Janssen Pharmaceutical, Beerse, Belgium), supple-
mented with diazepam (5mg/mL, 1mg/kg body weight, Val-
ium 10, Roche). In order to maintain the level of neurolep-
tanalgesia, increments of Hypnorm (0.1mL/kg) were given at 
30-min intervals during the operation.
 
 The surgical procedure consisted of the creation of two 
10?5mm full-thickness (approximately 2mm) cranial de-
fects, devoid of periosteum, using templates, in the parietal 
bones. The defects were produced using round stainless steel 
burs (1mm in diameter) on a low speed dental drill. Outlines 
of the defects were made initially by making holes of full 
thickness the parietal bone using a stainless steel wire tem-
plate bent to the required size of the defect. The holes were 
joined to complete the process. During the cutting of bone, 
copious amount of sterile saline was used for irrigation and 
to minimize thermal damage to the tissues. In the experimen-
tal animal, the defects were filled with collagen matrix (puri-
fied absorbable fibrillar collagen, Collagen Matrix Inc, NJ, 
USA) with 0.2 mL quercetin solution (Sigma-Aldrich, MO, 
USA, dissolved in water for injection to the concentration of 
100 mg/mL). The grafts were prepared 15 minutes before 
grafting. In the control animal, the defects were grafted with 
0.02 g of collagen matrix (purified fibrillar collagen, Colla-
gen Matrix, Inc NJ, USA) mixed with 0.2 mL water for in-
jection. 
 All wounds were closed with interrupted 3/0 black silk 
sutures. No attempt was made to approximate the periosteum 
to prevent the barrier effect. Postoperatively, the rabbits were 
given oxytetracycline hydrochloride daily for 10 days and 
buprenorphine hydrochloride for 2 weeks. 
 Two weeks after surgery, the animals were killed with 
sodium pentobarbitone. Immediately upon death, defects and 
surrounding tissue were removed for histological prepara-
tion. Tissues were fixed in 10% neutral buffered formal sa-
line solution, demineralized with K’s Decal Fluid (sodium 
formate/ formic acid), and finally double embedded in cel-
loidin/ paraffin wax. Serial, 5-?m-thick sections of the whole 
defect were cut perpendicular to the long axis. The slides 
were stained with Periodic acid-Schiff stain which allowed 
easy identification of new bone. 
RESULTS 
 Cytoplasmic total protein assay: The total protein con-
centrations were shown in Table 1 and graphically in Fig. 
(1). There were no statistical differences between the ex-
perimental groups and the control groups at any concentra-
tion of quercetin in any time interval. The total protein con-
centrations in general increased between the time intervals 
from 24 to 48 hours. 
 Biochemical detection of the alkaline phosphatase activ-
ity: The alkaline phosphatase activities, expressed as the 
ratio with the total protein, were shown in Table 2 and 
graphically in Fig. (2). There were no statistical differences 
between the experimental groups and the control groups at 
any concentrations of quercetin in short time intervals (24 
hours and 48 hours). At 72 hours, however, the activity is 
higher at in the experimental groups and was highly signifi-
cant (p<0.001, 32% increase) at the concentration of 10 μM 
of quercetin. 
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 In vivo study of quercetin: All animals remained in excel-
lent health throughout the course of the experiment and re-
covered rapidly after operation. There was no evidence of 
side effects or infection in any of the animals. This was as-
sessed by the in-house veterinary surgeons in the animal 
laboratory. 
 
Fig. (1). Comparison of amounts of the total protein (?g/mL) of 
quercetin on MC3T3-E1 cells. 
DISCUSSION 
 Total protein is an indication of the proliferative and bio-
synthetic capacities of bone cell cultures. Results showed 
that quercetin did not have great effect on these capacities on 
the MC3T3-E1, however, it significantly increased the alka-
line phosphatase activity in 72 hours by 32%. Showing that 
it had a stimulating effect on these preosteoblastic cells but 
the effect was only apparent at day three. 
 In this study unpaired t-test was used because it was nec-
essary to compare each value of a particular time and con-
centration of extract with the control rather than the group 
difference in general. It is possible that at some concentra-
tions and at some time frame there will be different in values 
between the experimental group and the control group but 
not the others, the result of this study showed this effect. 
 
Fig. (2). Comparison of alkaline phosphatase activity (mU/?g pro-
tein) of quercetin on MC3T3-E1 cells. 
 In the rabbit grafted with quercetin in collagen matrix, new 
bone was formed at the host bone-graft interface and tended to 
grow across the defect (Fig. 3). Integration of quercetin and 
collagen with the recipient bed was characterized by the pres-
ence of new bone. No cartilage was found. At higher magnifi-
cation (Fig. 4), new bone could be seen spanning across the  
 
Table 1. Comparison of Amounts of the Total Protein (μg/mL) of Quercetin on MC3T3-E1 Cells (Mean±SD). p-Value was Derived 
from Unpaired T Test Comparing the Experimental Group with the Control 
 
Concentration of Quercetin (μM) 0 (Control) 0.1 1 10 
Total Protein, 24 hours (μg/mL) 198.69±41.26 177.27±28.62 184.83±25.16 162.15±30.90 
p-value - NS NS NS 
Total Protein, 48 hours (μg/mL) 344.86±37.38 337.30±23.64 329.74±12.00 300.76±14.48 
p-value - NS NS NS 
Total Protein, 72 hours (μg/mL) 371.32±62.33 328.48±12.60 324.70±19.52 313.36±11.18 
p-value - NS NS NS 
NS: p> or =0.05, not statistical significant. 
 
Table 2. The Alkaline Phosphatase Activity (mU/μg Protein) of Quercetin on MC3T3-E1 Cells (MEAN±SD). p-Value was Derived 
from Unpaired T Test Comparing the Experimental Group with the Control. 
 
Concentration of Quercetin (μM) 0 (Control) 0.001 0.005 0.01 
ALP, 24 hours (mU/μg protein) 105.50±12.78 94.32±15.58 83.68±8.21 100.38±12.59 
p-value - NS NS NS 
ALP, 48 hours (mU/μg protein) 240.17±24.19 227.95±15.00 220.32±19.42 239.53±25.82 
p-value - NS NS NS 
ALP, 72 hours (mU/μg protein) 326.94±25.91 345.07±25.38 352.02±26.12 431.87±26.82 
p-value - NS NS p<0.001 
NS: p> or =0.05, not statistical significant. 
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Fig. (3). Photomicrograph of bony defect grafted with quercetin in collagen matrix on day 14. New bone (N) can be seen spanning across the 
defect. H = Host bone. Some collagen matrix (C) remained at the centre of the bony defect (Periodic acid-Schiff stain, original magnification 
?40). 
                 (a)      (b)      (c) 
      
(d)      (e) 
   
Fig. (4). (a)-(e). Photomicrograph of bony defect grafted with quercetin in collagen matrix on day 14 (higher magnification). New bone (N) 
can be seen spanning across the defect and growing towards the collagen matrix where the quercetin was releasing out. H = Host bone. Some 
collagen matrix (C) remained at the centre of the bony defect (Periodic acid-Schiff stain, original magnification ?100). 
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defect and growing towards and amalgamating with the colla-
gen matrix where the quercetin was releasing out. 
 In the control rabbit new bone was formed at the host 
bone-graft interface. Some collagen fibers were present at 
the centre of the defects (Fig. 5). In both rabbits, the defect 
was healed, with fibrous tissue bridging across the defect. 
 These results demonstrated that quercetin significantly 
increased bone cell activities without significantly affecting 
their proliferation. As we also performed a qualitative as-
sessment of quercetin solution in bone defect, for example, 
to check whether new bone will form or whether a severe 
inflammatory response will occur. These differences were 
compatible with the histological picture of the animal study. 
This is the first study that demonstrated the biological possi-
bility of quercetin of causing new bone forming across the 
bone defect in this animal model in 14 days. Therefore this 
study discovered the potential of quercetin to be used as a 
local osteogenic agent. Further studies on various gene ex-
pressions on quercetin on osteoblasts are needed to confirm 
the actual stimulation mechanisms and to carry out a quanti-
tative assessment of the amount of new bone formation of 
this extract compared with control with a greater sample 
size. 
 Prouilleta et al.
 
(Prouilleta BP 2004) [15] showed that 
quercetin in the range of 1-50 mM, increase the activity of 
ALP in MG-63 human osteoblasts without any significant 
cytotoxic effect on the cells. The maximal stimulatory effect 
on ALP was observed after 48 hours of treatment with 50 
mM quercetin. They also demonstrated that cycloheximide, a 
well known protein synthesis inhibitor, prevented the quer-
cetin-induced ALP activation, indicating that de novo protein 
synthesis is essential for this response. Moreover, an activa-
tion of the ERK pathway is required for the observed phe-
nomenon, because of the markedly reduction of the enhanc-
ing action of quercetin by MEK inhibitor PD 98059. The fact 
that ICI 182780, an antagonist of the ER, also prevents the 
quercetin-induced increase in ALP activity, indicates that 
this receptor is directly involved in the effect of quercetin. 
This study showed quercetin increased the ALP activity in 
MC3T3-E1 cells at the concentration of 10μM at 72 hours, 
showing the action of quercetin on different osteoblastic cell 
lines may be different. Further research is needed to compare 
the effect of quercetin on different osteoblastic cell lines 
under the same conditions. 
 Recently, the effects of quercetin on the differentiation 
and proliferation of human adipose tissue-derived stromal 
cells (hADSC) were determined (Kim BP 2006) [16]. Quer-
cetin was found to increase osteogenic differentiation in a 
dose-dependent manner. Quercetin pretreatment adminis-
tered prior to the induction of differentiation also exerted 
stimulatory effects on the osteogenic differentiation of 
hADSC. RT-PCR and real time PCR analysis showed that 
quercetin treatment induced an increase in the expression of 
osteopontin, BMP2, alkaline phosphatase and Runx2. Quer-
cetin inhibited the proliferation of hADSC, but did not affect 
their survival. The pretreatment of quercetin increased ERK 
phosphorylation during osteogenic differentiation, although 
it did not increase ERK activity in control culture condition. 
ICI182780, a specific estrogen receptor antagonist, failed to 
inhibit the effects of quercetin on osteogenic differentiation. 
These findings indicated that quercetin enhances osteogenic 
differentiation via an independent mechanism from ER acti-
vation. 
 Further research on various gene expressions in os-
teoblasts, mesenchymal cells and endothelial cells during the 
early healing of quercetin in collagen matrix is needed to 
confirm the mechanism of its osteogenic effect. 
 This study has considerable significance as quercetin is a 
commonly used health supplement. It gained interests in 
research by its multiple health maintenance effects. 
 This is the first study that demonstrated quercetin local 
osteogenic effect and its possibility in causing bone forma-
tion at the centre of the bone defect, which was rare with 
other osteogenic agents (Wong BJOMS 2003) [14] (Wong 
JOMS 2006) [17] (Wong Biomaterials 2007) [18] (Wong 
OC 2007) [19] (Wong BJMRA in press) [20]. The limita-
tions of this study are: Firstly, this study is looking at the 
histological picture qualitatively about the effect of grafting 
quercetin in bone defects, a quantitative assessment is 
 
Fig. (5). Photomicrograph of bony defect grafted with collagen matrix (positive control) in day 14. No bone could be seen across the defect 
except for a little new bone (N) near the ends of the host bone (H). Collagen matrix (C) remained across the bone defect (Periodic acid-Schiff 
stain, original magnification ?40). 
32    The Open Orthopaedics Journal, 2008, Volume 2 Wong and Rabie 
needed to compare the amount of bone formed between the 
experimental and control group with a bigger sample size to 
show whether quercetin increases in bone formation. Sec-
ondly, there are concerns about the effectiveness of oestro-
gen replacement therapy in the prevention of osteoporosis, 
therefore, further studies are needed to determine the sys-
temic effect of quercetin on bone metabolism on bone before 
clinical trials for its use in the prevention of osteoporosis to 
be considered. 
CONCLUSION 
 Specific concentration of quercetin increased alkaline 
phosphatase activity of MC3T3-E1 cells in vitro. This study 
also discovered the potential of quercetin to be used as a 
local osteogenic agent in vivo. Further research is needed to 
optimize its use and to gain further understanding on its bone 
forming mechanism. 
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